Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response

• Published in: Quality of life research 2021-12, Vol.30 (12), p.3501-3509
• Main Authors: Miyasaka, Akio, Yoshida, Yuichi, Suzuki, Akiko, Takikawa, Yasuhiro
• Format: Article
• Language: English
• Subjects: Aged; Antiviral Agents - therapeutic use; Antiviral drugs; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic - drug therapy; Humans; Infant; Interferon; Medicine; Medicine & Public Health; Public Health; Quality of life; Quality of Life - psychology; Quality of Life Research; Ribavirin - therapeutic use; Sociology; Sofosbuvir - therapeutic use; Treatment Outcome
• ISSN: 0962-9343; 1573-2649
• DOI: 10.1007/s11136-021-02874-6

Purpose Long-term effects on patient health-related quality of life (HRQoL) after direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) are unknown. We assessed the impact of DAA-mediated HCV clearance on HRQoL from DAA initiation to 1 year after confirmed sustained virological response at 24 weeks post-treatment (SVR24). Methods HRQoL was evaluated using the eight-item Short Form Health Survey (SF-8). Chronic HCV-infected patients were treated for 12 weeks with sofosbuvir-based DAAs. SF-8 was administered at baseline, treatment cessation, SVR24, and 1-year post-SVR24. Results A total of 109 chronic HCV-infected patients were enrolled. The average SF-8 scores were higher than the Japanese national standard values for bodily pain (BP) and mental health at baseline and for general health at 1-year post-SVR24. None of the SF-8 scores differed significantly between baseline and 1-year post-SVR24. Regarding age, sex, liver status, and treatment regimen, the SF-8 scores at 1-year post-SVR24 were affected by only age; individuals aged